Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan (D-First)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2011 by Kanto CML Study Group.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
Takashi Kumagai, Kanto CML Study Group Identifier:
First received: September 18, 2011
Last updated: November 2, 2011
Last verified: November 2011